Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Yen · SciRah

Researcher profile · Semantic Scholar

K. Yen

Share profile

K. Yen — researcher profile on SciRah

h-index: 11
Works: 26
Citations: 4,357

Most-cited papers

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
B. Ramsey, Jane C. Davies, N. McElvaney, Elizabeth Tullis +15 more
2011New England Journal of Medicine2,094 citations Open access
Semantic Scholar
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
J. Clancy, S. M. Rowe, Frank J. Accurso, Moira L. Aitken +26 more
2011Thorax561 citations Open access
Semantic Scholar
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
J. Davies, C. Wainwright, G. Canny, M. Chilvers +8 more
2013American Journal of Respiratory and Critical Care Medicine504 citations Open access
Semantic Scholar
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
N. Hanania, M. Noonan, J. Corren, P. Korenblat +14 more
2015Thorax372 citations Open access
Semantic Scholar
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
P. Flume, T. Liou, D. Borowitz, Haihong Li +3 more
2012Chest335 citations Open access
Semantic Scholar
Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE)
E. Simpson, C. Flohr, L. Eichenfield, T. Bieber +10 more
2018Journal of American Academy of Dermatology305 citations Open access
Semantic Scholar
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
P. Korenblat, E. Kerwin, I. Leshchenko, K. Yen +7 more
2018Respiratory Medicine50 citations Open access
Semantic Scholar
Bidi cigarettes: An emerging threat to adolescent health.
K. Yen, Elizabeth Hechavarria, S. Bostwick
2000Archives of Pediatrics & Adolescent Medicine36 citations
Semantic Scholar
Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials
N. Hanania, M. Noonan, J. Corren, P. Korenblat +11 more
201418 citations Open access
Semantic Scholar
WS6.5 Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation
J. Davies, Haihong Li, K. Yen, R. Ahrens
201211 citations Open access
Semantic Scholar
WS6.4 Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR Mutation
E. McKone, H. Li, K. Yen, J. Davies
201211 citations Open access
Semantic Scholar
46 Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation
T. Altes, Mac Johnson, G. Miller, J. Mugler +8 more
201210 citations Open access
Semantic Scholar
The Effect Of Ivacaftor, An Investigational CFTR Potentiator, On Hyperpolarized Noble Gas Magnetic Resonance Imaging In Subjects With Cystic Fibrosis Who Have The G551D-CFTR Mutation
T. Altes, Mac Johnson, J. Mugler, G. Miller +9 more
2012Asian Test Symposium8 citations
Semantic Scholar
A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062)
K. Wagner, B. Wong, B. Byrne, Cuixia Tian +12 more
2019Neurology7 citations
Semantic Scholar
61* VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
P. Flume, D. Borowitz, T. Liou, Haihong Li +3 more
20117 citations Open access
Semantic Scholar
43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation
A. Quittner, B. Ramsey, Q. Dong, K. Yen +1 more
20125 citations Open access
Semantic Scholar
WS6.3 Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation
D. Borowitz, B. Ramsey, Q. Dong, K. Yen +1 more
20125 citations Open access
Semantic Scholar
Nasal Biomarkers Characterization In Lebrikizumab Bronchoscopy Study (CLAVIER)
Fang Cai, Francis Abreu, Han-Ting Ding, D. Choy +12 more
20183 citations
Semantic Scholar
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation
J. Elborn, C. Wainwright, I. Sermet-Gaudelus, S. Rodriguez +2 more
20123 citations
Semantic Scholar
Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation
E. McKone, S. Rodriguez, K. Yen, J. Davies
20123 citations
Semantic Scholar
44 Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation
M. Griese, B. Ramsey, S. Rodriguez, K. Yen +1 more
20123 citations Open access
Semantic Scholar
Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation
B. Plant, B. Ramsey, K. Yen, Q. Dong +2 more
2011European Respiratory Journal3 citations
Semantic Scholar
Pulmonary Effects Of The Investigational CFTR Potentiator, Ivacaftor, In Two Phase 3 Trials In Subjects With CF Who Have The G551D-CFTR Mutation
S. Elborn, C. Wainwright, I. Sermet-Gaudelus, S. Nasr +3 more
2012Asian Test Symposium2 citations
Semantic Scholar
Cystic Fibrosis Foundation Therapeutics, Inc. Therapeutics Development Network Center for Sweat Analysis Medical Director: F. Accurso, M.D. (720 777 2522) Center for Sweat Analysis Publications
J. Clancy, S. Rowe, M. Ashlock, S. Donaldson +12 more
20121 citations
Semantic Scholar
A multinational , randomized , double-blind , placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime ( TRO 19622 / RG 6083 ) in patients with Type 2 or non-ambulatory Type 3 spinal muscular atrophy
E. Bertini, E. Dessaud, E. Mercuri, J. Kirschner +16 more
20190 citations
Semantic Scholar
Cystic fibrosis : detection and monitoring of early lung disease 4655
B. Plant, B. Ramsey, K. Yen, Q. Dong +22 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Rodriguez×9
Invite
S. Rodriguez — researcher profile on SciRah
B. Ramsey×8
Invite
B. Ramsey — researcher profile on SciRah
J. Elborn×8
Invite
J. Elborn — researcher profile on SciRah
C. Ordoñez×6
Invite
C. Ordoñez — researcher profile on SciRah

×5

Invite

Q. Dong — researcher profile on SciRah

Invite

J. Davies — researcher profile on SciRah

Invite

E. McKone — researcher profile on SciRah

Invite

Haihong Li — researcher profile on SciRah

Invite

W. Putnam — researcher profile on SciRah

Invite

J. Matthews — researcher profile on SciRah

Invite

M. Botfield — researcher profile on SciRah

C. Wainwright×3

Invite

C. Wainwright — researcher profile on SciRah